Abstract:Newcastle disease is still causing huge economic losses and devastating outbreaks in poultry flocks despite implementation of extensive vaccination programs. Five commercial broiler chicken groups were established as G1 (non-vaccinated, non-challenged group) and G2 (non-vaccinated, challenged group), and 3 vaccinated challenged groups as G3 (vaccinated with heterologous inactivated Newcastle disease virus (NDV) genotype II (NDV II) vaccine), G4 (vaccinated with homologous inactivated NDV genotype VII (NDV VII) vaccine), and G5 (vaccinated with bivalent (heterologous inactivated NDV II plus H5) vaccine) were used. Challenge test was done using a velogenic NDV genotype VII (vNDV VII) at 28-d olds. Respiratory signs, greenish diarrhea, and obvious post-mortem lesions of vNDV VII appeared in all the challenged birds whether vaccinated or not. In addition, the mortality rate decreased from 93.3% in G2 to 46.7%, 53.3%, and 66.7% in G4, G5, and G3, respectively. Overall, 2 wk postchallenge; body weight loss (%) had increased mainly in G2, with some improvement in chickens in G4 followed by G5 and chickens of G3 showed the least improvement. At 28 d (day of challenge), the highest hemagglutination inhibition values were 4.3 and 5.4 log2 in chickens in G4 and G5, respectively, which increased in all groups after the challenge. Cytokine (IL-6 and IFN-γ) levels were significantly higher (P < 0.05) in the vaccinated groups than that in the non-vaccinated group, especially in G5. Viral shedding in the trachea was higher than that in the cloacal swabs in all vaccinated and non-vaccinated challenged groups with peak shedding on the 6th day post challenge for both swabs, and the lowest viral shedding titers were observed in chickens in G5. Therefore, the use of homologous genotype NDV with inactivated vaccine conferred a higher clinical protection in terms of body weight loss and mortality against vNDV VII challenge in broiler chickens; however, the heterologous vaccine used in G5 induced the highest cell-mediated immune response and hemagglutination inhibition titers with the lowest viral shedding titer.

Evaluation of avian paramyxovirus serotypes 2 to 10 as vaccine vectors in chickens previously immunized against Newcastle disease virus

Development and Evaluation of Newcastle Disease - Avian Influenza Bivalent Vector Vaccines in Commercial Chickens.

A Novel Recombinant Attenuated Newcastle Disease Virus Expressing H9 Subtype Hemagglutinin Protected Chickens from Challenge by Genotype VII Virulent Newcastle Disease Virus and H9N2 Avian Influenza Virus.

Effects of Newcastle disease virus vaccine antibodies on the shedding and transmission of challenge viruses

Experimental Infection of Mice with Avian Paramyxovirus Serotypes 1 to 9.

Chimeric Newcastle disease virus-vectored vaccine protects chickens against H9N2 avian influenza virus in the presence of pre-existing NDV immunity

Evaluation of Fusion Protein Cleavage Site Sequences of Newcastle Disease Virus in Genotype Matched Vaccines

Newcastle Disease Virus Vectored Chicken Infectious Anaemia Vaccine Induces Robust Immune Response in Chickens

Replication, Neurotropism, and Pathogenicity of Avian Paramyxovirus Serotypes 1-9 in Chickens and Ducks.

RETRACTED: Modified Newcastle Disease Virus Vectors Expressing the H5 Hemagglutinin Induce Enhanced Protection Against Highly Pathogenic H5N1 Avian Influenza Virus in Chickens

Infectivity of Wild Bird-Origin Avian Paramyxovirus Serotype 1 and Vaccine Effectiveness in Chickens

Use of live attenuated recombinant Newcastle disease virus carrying avian paramyxovirus 2 HN and F protein genes to enhance immune responses against species A rotavirus VP6 protein

Construction and Evaluation of the Immunogenicity and Protective Efficacy of Recombinant Replication-Deficient Human Adenovirus-5 Expressing Genotype VII Newcastle Disease Virus F Protein and Infectious Bursal Disease Virus VP2 Protein

Newcastle Disease Virus-Based Live Attenuated Vaccine Completely Protects Chickens and Mice from Lethal Challenge of Homologous and Heterologous H5n1 Avian Influenza Viruses

Assembly and Immunological Properties of a Bivalent Virus-Like Particle (VLP) for Avian Influenza and Newcastle Disease

In vivo challenge studies on vaccinated chickens indicate a virus genotype mismatched vaccine still offers significant protection against NDV

Chimeric Newcastle Disease Virus-like Particles Containing DC-Binding Peptide-Fused Haemagglutinin Protect Chickens from Virulent Newcastle Disease Virus and H9N2 Avian Influenza Virus Challenge

The Advancement on Recombinant Newcastle Disease Virus As a Vaccine Vector

Immunogenicity and protective efficacy of a multivalent herpesvirus vectored vaccine against H9N2 low pathogenic avian influenza in chicken

Comparative efficacy of commercial inactivated Newcastle disease virus vaccines against Newcastle disease virus genotype VII in broiler chickens

Low pathogenic avian influenza (H9N2) in chicken: Evaluation of an ancestral H9-MVA vaccine